

Commercial House, Eden Island Mahe, Seychelles https://seychellesmedicalservices.com

Mobile: +248 4366999



MOLECULAR DIAGNOSIS REPORT RAPID ANTIGEN TESTING FOR SARS-COV-2 VIRUS RNA

PATIENT SURNAME / GIVEN NAME(S)

OLEKSANDR KRAVCHENKO

GENDER DATE OF BIRTH DOCUMENT TYPE / DOCUMENT NUMBER

Male 1967-03-31 Passport / FF354367

SAMPLE COLLECTION DATE & TIME **2023-06-16 09:00:00**

SAMPLE TYPE

Naso Pharyngeal Swab

SAMPLE REFERENCE NO

230848

INTERPRETATION / FINAL FINDINGS



NEGATIVE FINDINGS FOR RAPID ANTIGEN SARS-COV-2 VIRUS RNA

PROCEDURE

Detection of SARS-CoV2 Viral RNA performed on Real Time Polymerase Chain Reaction (RT-PCR). RNA is extracted by using abGenix RNA/DNA extractor system. Amplification of extracted RNA was performed by Macurra SARS-Cov-2 fluorescent PCR Kit by using abGenixQ Real-Time PCR system. Positive and negative controls are included in each run to confirm validity and accuracy of the test.

INTERPRETATION

This assay does qualitative detection for SARS-CoV2 Virus that covers three genes (E-Gene, N-Gene & ORF1ab) Both positive and negative controls for the tested virus showed expected result.

Not detected results may not always rule out current or future infection. Please correlate with clinical findings and repeat if necessary. Positive result indicates the RNA from SARS-CoV2 was detected and patient is infected

Negative result indicates SARS-Cov2-Virus not present in specimen above the limit of detection

LIMITATIONS

The detection of viral RNA is dependent on the viral load in the specimen representing an acute infection, that is early in the disease. Preanalytical variables (i.e. specimen quality, handling/transport conditions) may also adversely affect the results & analytical variables perhaps Virus mutation. The performance characteristics of this test has been validated in the molecular virology diagnostic unit of the Seychelles Medical Services, and is continuously monitored as part of quality assurance procedures, including enrolment with local Head

REPORT DATE

PERFORMED

APPROVED

June 16, 2023

Lead Analyst - Rehmat HPC21/0791 Consultant - S. Raza HPC20/0737